Continued access to treatment from a finished Lilly study
Part of Cancer clinical trials.
This study lets people who were already getting benefit from a Lilly study treatment keep taking it after the main study ends, so doctors can continue to monitor their safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must currently be in a Lilly study that has ended, and you must be benefiting from the treatment.
- The study you are in must have a special 'continued access' option available.
- You cannot be in any other medical research that could conflict with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This program provides access to two investigational drugs, balstilimab and zalifrelimab, for people who have already completed a related clinical trial. It aims to offer continued treatment options for those who may benefit.
This program lets people who have already finished a clinical trial of the study drug LP352 and are still getting benefit from it keep receiving it. It's designed for those with developmental epileptic encephalopathy (a type of epilepsy that starts in childhood and affects development).
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
This is a follow-up study for people with ALS who have already completed another Eli Lilly ALS treatment trial. Researchers want to continue testing a new drug (LY4256984) in people who tolerated the previous treatment well.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.